Larry I. Magpantay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Larry I. Magpantay has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Otoniel Martínez-Maza
AIDS Institute, University of California Los Angeles
6 shared publications - Lynn I. Levin
Statistics and Epidemiology Branch, Walter Reed Army Institute of Research, Silver Spring, MD
5 shared publications - Aizen J. Marrogi
Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, MD
4 shared publications - Bong K. Kim
Armed Forces Institute of Pathology, Washington DC
4 shared publications - Christina Michelle Ramirez Kitchen
Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
4 shared publications - Eileen L. Liao
Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA
4 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Exposure to specific particulate matter (PM) sources and constituents are differentially associated with circulating immune biomarkers in women
BACKGROUNDParticulate matter (PM) arises from a number of sources, and its composition reflects this diversity. Prior literature on PM2.5 and PM10 components in relation to circulating immune markers is scant, and nonexistent for PM0.1. Because PM toxicity depends on its particle size, source, and chemical/biological constituents, we hypothesized that specific PM components and sources may disproportionately drive immune responses.METHODSWe evaluated associations between source- and component-resolved PM0.1, PM2.5, and PM10 at 3 time lags (1-, 3-, and 12-months prior to blood draw) and 15 circulating immune markers among 1,898 female participants in the California Teachers Study who provided blood samples in 2015. Using interquartile range increases in PM sources/components and immune marker levels in quartiles, we fit multinomial logistic regression models and applied Bonferroni correction.RESULTSHigher PM2.5 elemental carbon at all exposure periods were positively associated with elevated circulating IL-1β, sCD27, and sTNFR2. Associations were strongest for 12-month elemental carbon with increased odds for the highest quartile of IL1β (ORQuartile4=2.91, 95% CI=1.92-4.43), sCD27 (ORQuartile 4=2.04, 95% CI=1.34-3.12) and sTNFR2 (ORQuartile4=2.68, 95% CI=1.72-4.18). Associations for PM10 and PM0.1 paralleled PM2.5, with two exceptions. PM10 off-road diesel was associated with elevated IL-8 at the 12-month (ORQuartile4=1.71, 95% CI=1.25-2.34) and 3-month exposure lags (ORQuartile4=1.74, 95% CI=1.33-2.26) and with CCL2 at the 3-month (ORQuartile4=1.57, 95% CI=1.20-2.04) and 1-month exposure lags (ORQuartile4=1.48, 95% CI=1.14-1.91).CONCLUSIONSThese findings support heterogeneous biological effects of PM sources/components, highlighting the importance of considering this heterogeneity when interpreting PM mass associations across populations.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessExposure to specific particulate matter (PM) sources and constituents are differentially associated with circulating immune biomarkers in women
BACKGROUNDParticulate matter (PM) arises from a number of sources, and its composition reflects this diversity. Prior literature on PM2.5 and PM10 components in relation to circulating immune markers is scant, and nonexistent for PM0.1. Because PM toxicity depends on its particle size, source, and chemical/biological constituents, we hypothesized that specific PM components and sources may disproportionately drive immune responses.METHODSWe evaluated associations between source- and component-resolved PM0.1, PM2.5, and PM10 at 3 time lags (1-, 3-, and 12-months prior to blood draw) and 15 circulating immune markers among 1,898 female participants in the California Teachers Study who provided blood samples in 2015. Using interquartile range increases in PM sources/components and immune marker levels in quartiles, we fit multinomial logistic regression models and applied Bonferroni correction.RESULTSHigher PM2.5 elemental carbon at all exposure periods were positively associated with elevated circulating IL-1β, sCD27, and sTNFR2. Associations were strongest for 12-month elemental carbon with increased odds for the highest quartile of IL1β (ORQuartile4=2.91, 95% CI=1.92-4.43), sCD27 (ORQuartile 4=2.04, 95% CI=1.34-3.12) and sTNFR2 (ORQuartile4=2.68, 95% CI=1.72-4.18). Associations for PM10 and PM0.1 paralleled PM2.5, with two exceptions. PM10 off-road diesel was associated with elevated IL-8 at the 12-month (ORQuartile4=1.71, 95% CI=1.25-2.34) and 3-month exposure lags (ORQuartile4=1.74, 95% CI=1.33-2.26) and with CCL2 at the 3-month (ORQuartile4=1.57, 95% CI=1.20-2.04) and 1-month exposure lags (ORQuartile4=1.48, 95% CI=1.14-1.91).CONCLUSIONSThese findings support heterogeneous biological effects of PM sources/components, highlighting the importance of considering this heterogeneity when interpreting PM mass associations across populations.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Background:To examine the contribution of B-cell activation molecules to B-cell follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), a prospective study was conducted using pre-diagnosis serial serum samples from the US Department of Defense Serum Repository.Methods:Each case (n = 142 FL, n = 211 DLBCL) was matched to two controls on age, gender, race, military branch, and blood collection dates. Immune activation molecules (IL1β, IL2, IL4, IL5, IL6, IL10, IL12, CXCL13, IL8, TNFα, IFNγ, GM-CSF, VEGF, sCD30, IgE) were quantified using ELISA or multiplex immunometric (Luminex) assay. Longitudinal data were analyzed using linear mixed modeling. As serial specimens were collected over several years before diagnosis, we evaluated the temporal dynamics of these markers.Results:Increased serum levels of sCD30, CXCL13, and to a lesser extent IL10, were associated with both FL and DLBCL in cases compared with controls, with a median follow-up of 5.5 years from the earliest specimen collection to diagnosis date. Significant increasing sCD30 and CXCL13 trajectories for FL and DLBCL subtypes were noted starting at the earliest time points and with IL10 levels increasing significantly at time points closer to diagnosis.Conclusions:These results suggest that sCD30, CXCL13, and IL10 may contribute to the etiology of FL and DLBCL and are potential biomarkers for these non–Hodgkin lymphoma subtypes.Impact:The increasing trajectories of the B-cell activation molecules, sCD30, CXCL13, and to a lesser extent IL10, may indicate early disease-induced effects or reflect the chronic stimulation of B-cells that promotes the development of FL and DLBCL subtypes.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Background:To examine the contribution of B-cell activation molecules to B-cell follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), a prospective study was conducted using pre-diagnosis serial serum samples from the US Department of Defense Serum Repository.Methods:Each case (n = 142 FL, n = 211 DLBCL) was matched to two controls on age, gender, race, military branch, and blood collection dates. Immune activation molecules (IL1β, IL2, IL4, IL5, IL6, IL10, IL12, CXCL13, IL8, TNFα, IFNγ, GM-CSF, VEGF, sCD30, IgE) were quantified using ELISA or multiplex immunometric (Luminex) assay. Longitudinal data were analyzed using linear mixed modeling. As serial specimens were collected over several years before diagnosis, we evaluated the temporal dynamics of these markers.Results:Increased serum levels of sCD30, CXCL13, and to a lesser extent IL10, were associated with both FL and DLBCL in cases compared with controls, with a median follow-up of 5.5 years from the earliest specimen collection to diagnosis date. Significant increasing sCD30 and CXCL13 trajectories for FL and DLBCL subtypes were noted starting at the earliest time points and with IL10 levels increasing significantly at time points closer to diagnosis.Conclusions:These results suggest that sCD30, CXCL13, and IL10 may contribute to the etiology of FL and DLBCL and are potential biomarkers for these non–Hodgkin lymphoma subtypes.Impact:The increasing trajectories of the B-cell activation molecules, sCD30, CXCL13, and to a lesser extent IL10, may indicate early disease-induced effects or reflect the chronic stimulation of B-cells that promotes the development of FL and DLBCL subtypes.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Supplemental Figure 2 shows longitudinal case-control changes in mean levels of sCD30, CXCL13, and IL-10 prior to diagnosis in follicular lymphoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Supplemental Figure 2 shows longitudinal case-control changes in mean levels of sCD30, CXCL13, and IL-10 prior to diagnosis in follicular lymphoma
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Supplemental Figure 1 shows the longitudinal case-control changes in mean levels of sCD30, IL-10, CXCL13, TNF-α, and IFN-gamma prior to diagnosis in diffuse large B-cell lymphoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Supplemental Figure 1 shows the longitudinal case-control changes in mean levels of sCD30, IL-10, CXCL13, TNF-α, and IFN-gamma prior to diagnosis in diffuse large B-cell lymphoma
- 1 May 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (7) , 1254-1263
Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins
Late-onset conditions have been reported in young adult Hodgkin lymphoma (YAHL) survivors but the use of convenience controls may bias estimates. Thirty-five YAHL survivors and their unaffected co-twins completed an online questionnaire on such conditions. McNemar's test and conditional logistic and random-effects linear regression were used to assess differences. On average, YAHL survivors (54.3% monozygotic, 57.1% female) were 27.1 years at diagnosis and 29.7 years post-diagnosis at participation. Survivors had increased risk of secondary malignancy (OR = 4.33), cardiac (12 cases/0 co-twins), lung (6 cases/0 co-twins), and thyroid conditions (18 cases/0 co-twins), and increased utilization of cardiac (OR = 9.00) and thyroid tests (OR = 10.00) compared to their co-twin. Non-significant trends in life milestone achievement, including greater college degree attainment, earlier retirement, and fewer biological children, were also observed in YAHL survivors. Life satisfaction was significantly lower among YAHL survivors (p = .035). Decades after diagnosis, differences in late outcomes were observed in YAHL survivors compared to co-twin controls, providing a more accurate assessment of the late effects of YAHL.
- 1 May 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (7) , 1254-1263
Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins
Late-onset conditions have been reported in young adult Hodgkin lymphoma (YAHL) survivors but the use of convenience controls may bias estimates. Thirty-five YAHL survivors and their unaffected co-twins completed an online questionnaire on such conditions. McNemar's test and conditional logistic and random-effects linear regression were used to assess differences. On average, YAHL survivors (54.3% monozygotic, 57.1% female) were 27.1 years at diagnosis and 29.7 years post-diagnosis at participation. Survivors had increased risk of secondary malignancy (OR = 4.33), cardiac (12 cases/0 co-twins), lung (6 cases/0 co-twins), and thyroid conditions (18 cases/0 co-twins), and increased utilization of cardiac (OR = 9.00) and thyroid tests (OR = 10.00) compared to their co-twin. Non-significant trends in life milestone achievement, including greater college degree attainment, earlier retirement, and fewer biological children, were also observed in YAHL survivors. Life satisfaction was significantly lower among YAHL survivors (p = .035). Decades after diagnosis, differences in late outcomes were observed in YAHL survivors compared to co-twin controls, providing a more accurate assessment of the late effects of YAHL.
- Open Access
- 30 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (22) , 1928-1931
Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years
Tumor cells in classic Hodgkin lymphoma produce high quantities of the thymus- and activation-related chemokine (TARC). We measured TARC levels in prediagnostic serum samples and found strikingly increased values in the vast majority of patients, as early as 6 years before diagnosis.
- 30 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (22) , 1928-1931
Open AccessElevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years
Tumor cells in classic Hodgkin lymphoma produce high quantities of the thymus- and activation-related chemokine (TARC). We measured TARC levels in prediagnostic serum samples and found strikingly increased values in the vast majority of patients, as early as 6 years before diagnosis.
- 21 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 233-241
Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Background: To examine the contribution of B-cell activation molecules to B-cell follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), a prospective study was conducted using pre-diagnosis serial serum samples from the US Department of Defense Serum Repository. Methods: Each case (n = 142 FL, n = 211 DLBCL) was matched to two controls on age, gender, race, military branch, and blood collection dates. Immune activation molecules (IL1β, IL2, IL4, IL5, IL6, IL10, IL12, CXCL13, IL8, TNFα, IFNγ, GM-CSF, VEGF, sCD30, IgE) were quantified using ELISA or multiplex immunometric (Luminex) assay. Longitudinal data were analyzed using linear mixed modeling. As serial specimens were collected over several years before diagnosis, we evaluated the temporal dynamics of these markers. Results: Increased serum levels of sCD30, CXCL13, and to a lesser extent IL10, were associated with both FL and DLBCL in cases compared with controls, with a median follow-up of 5.5 years from the earliest specimen collection to diagnosis date. Significant increasing sCD30 and CXCL13 trajectories for FL and DLBCL subtypes were noted starting at the earliest time points and with IL10 levels increasing significantly at time points closer to diagnosis. Conclusions: These results suggest that sCD30, CXCL13, and IL10 may contribute to the etiology of FL and DLBCL and are potential biomarkers for these non–Hodgkin lymphoma subtypes. Impact: The increasing trajectories of the B-cell activation molecules, sCD30, CXCL13, and to a lesser extent IL10, may indicate early disease-induced effects or reflect the chronic stimulation of B-cells that promotes the development of FL and DLBCL subtypes.
- 21 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 233-241
Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes
Background: To examine the contribution of B-cell activation molecules to B-cell follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), a prospective study was conducted using pre-diagnosis serial serum samples from the US Department of Defense Serum Repository. Methods: Each case (n = 142 FL, n = 211 DLBCL) was matched to two controls on age, gender, race, military branch, and blood collection dates. Immune activation molecules (IL1β, IL2, IL4, IL5, IL6, IL10, IL12, CXCL13, IL8, TNFα, IFNγ, GM-CSF, VEGF, sCD30, IgE) were quantified using ELISA or multiplex immunometric (Luminex) assay. Longitudinal data were analyzed using linear mixed modeling. As serial specimens were collected over several years before diagnosis, we evaluated the temporal dynamics of these markers. Results: Increased serum levels of sCD30, CXCL13, and to a lesser extent IL10, were associated with both FL and DLBCL in cases compared with controls, with a median follow-up of 5.5 years from the earliest specimen collection to diagnosis date. Significant increasing sCD30 and CXCL13 trajectories for FL and DLBCL subtypes were noted starting at the earliest time points and with IL10 levels increasing significantly at time points closer to diagnosis. Conclusions: These results suggest that sCD30, CXCL13, and IL10 may contribute to the etiology of FL and DLBCL and are potential biomarkers for these non–Hodgkin lymphoma subtypes. Impact: The increasing trajectories of the B-cell activation molecules, sCD30, CXCL13, and to a lesser extent IL10, may indicate early disease-induced effects or reflect the chronic stimulation of B-cells that promotes the development of FL and DLBCL subtypes.